

Francois Ducray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6295770/publications.pdf>

Version: 2024-02-01

158
papers

7,111
citations

71097

41
h-index

66906

78
g-index

176
all docs

176
docs citations

176
times ranked

8900
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases. <i>Neurosurgical Review</i> , 2022, 45, 683-699.	2.4	4
2	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
3	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfilER trial. <i>Medical Oncology</i> , 2022, 39, 4.	2.5	3
4	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 414-423.	3.7	3
5	Gyriform infiltration as imaging biomarker for molecular glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 511-521.	2.9	9
6	Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases. <i>Neurosurgical Review</i> , 2022, 45, 2797-2809.	2.4	3
7	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, e866-e875.	1.1	44
8	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab078.	0.7	2
9	Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab061.	0.7	28
10	Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1843-1856.	2.5	5
11	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. <i>Journal of Neurology</i> , 2021, 268, 2515-2522.	3.6	4
12	Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. <i>Oncologist</i> , 2021, 26, e838-e846.	3.7	10
13	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , 2021, 153, 55-64.	2.9	8
14	TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. <i>Oncologist</i> , 2021, 26, 647-e1304.	3.7	3
15	Intracranial non-myxoid angiomatoid fibrous histiocytoma with EWSR1-CREB1 transcript fusion treated with doxorubicin: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 131.	1.0	5
16	Sustained Tumor Control With MAPK Inhibition in BRAF V600E-Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.1	16
17	Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 148-159.	1.6	2
18	Alterations of cerebral microcirculation in peritumoral edema: feasibility of in vivo sidestream dark-field imaging in intracranial meningiomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa108.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	1.2	41
20	Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106006.	1.4	7
21	Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients. <i>Neurosurgery</i> , 2020, 87, E513-E519.	1.1	10
22	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	58
23	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. <i>Journal of Neurology</i> , 2020, 267, 2083-2089.	3.6	28
24	Central nervous system complications associated with immune checkpoint inhibitors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 772-778.	1.9	92
25	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	129
26	CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1519-1528.	1.2	107
27	The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 175.	5.2	8
28	Highlights of the inaugural ten “the launch of Neuro-Oncology Advances. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz2016.	0.7	0
29	Letter to the Editor. <i>Neuro-Oncology</i> , 2019, 21, 1482-1482.	1.2	0
30	Conventional MRI radiomics in patients with suspected early- or pseudo-progression. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz2019.	0.7	14
31	Multinodular and Vacuolating Posterior Fossa Lesions of Unknown Significance. <i>American Journal of Neuroradiology</i> , 2019, 40, 1689-1694.	2.4	10
32	Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients. <i>Revue Neurologique</i> , 2019, 175, 534-543.	1.5	8
33	Charcot-Marie-Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: A case report and review of the literature. <i>Revue Neurologique</i> , 2019, 175, 486-489.	1.5	2
34	A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549“BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 537-545.	3.8	1
35	Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. <i>Journal of Neuro-Oncology</i> , 2019, 143, 515-523.	2.9	11
36	Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2019, 9, 177.	2.8	17

#	ARTICLE	IF	CITATIONS
37	Simultaneous occurrence of giant cell arteritis and cerebral amyloid angiopathy. Rheumatology, 2019, 58, 1503-1505.	1.9	1
38	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. Neurosurgery, 2019, 85, E448-E456.	1.1	20
39	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. Journal of Neurology, 2019, 266, 195-206.	3.6	58
40	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. European Journal of Neurology, 2019, 26, 639-650.	3.3	29
41	The molecular landscape of glioma in patients with Neurofibromatosis 1. Nature Medicine, 2019, 25, 176-187.	30.7	145
42	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. Journal of Neurology, 2019, 266, 398-410.	3.6	31
43	A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA). Neuro-Oncology Advances, 2019, 1, vdz043.	0.7	8
44	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology, 2018, 20, 716-718.	1.2	8
45	Glioblastoma as differential diagnosis of autoimmune encephalitis. Journal of Neurology, 2018, 265, 669-677.	3.6	30
46	Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. Journal of Neuro-Oncology, 2018, 138, 141-145.	2.9	6
47	Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 789-792.	1.9	41
48	Characteristics of cerebellar glioblastomas in adults. Journal of Neuro-Oncology, 2018, 136, 555-563.	2.9	31
49	Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation. Revue Neurologique, 2018, 174, 265-266.	1.5	6
50	Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. Journal of Neuro-Oncology, 2018, 136, 533-539.	2.9	16
51	Molecular classification of adult gliomas: recent advances and future perspectives. Current Opinion in Oncology, 2018, 30, 375-382.	2.4	7
52	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathologica Communications, 2018, 6, 89.	5.2	12
53	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. Oncologist, 2018, 23, 1500-1510.	3.7	6
54	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. Journal of Neurology, 2018, 265, 2190-2200.	3.6	64

#	ARTICLE	IF	CITATIONS
55	Motor neuron disease of paraneoplastic origin: a rare but treatable condition. <i>Journal of Neurology</i> , 2018, 265, 1590-1599.	3.6	31
56	Returning to work after multimodal treatment in glioblastoma patients. <i>Neurosurgical Focus</i> , 2018, 44, E17.	2.3	29
57	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.1	49
58	Brain Gliomas in the Elderly. , 2017, , 119-140.		0
59	Characteristics of H3 K27M-mutant gliomas in adults. <i>Neuro-Oncology</i> , 2017, 19, 1127-1134.	1.2	207
60	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 347-358.	1.9	24
61	Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. <i>European Journal of Cancer</i> , 2017, 72, 12-19.	2.8	14
62	Anaplastic gliomas in adults: an update. <i>Current Opinion in Oncology</i> , 2017, 29, 434-442.	2.4	10
63	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e371.	6.0	64
64	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. <i>Brain Pathology</i> , 2017, 27, 567-579.	4.1	16
65	Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. <i>Cancer Biomarkers</i> , 2017, 20, 435-441.	1.7	13
66	Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. <i>Cancer Medicine</i> , 2016, 5, 1753-1764.	2.8	12
67	Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , 2016, 18, 888-890.	1.2	16
68	The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1129-1136.	1.2	85
69	Neuroleptic intolerance in patients with anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e280.	6.0	139
70	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016, 132, 625-634.	7.7	85
71	Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. <i>JAMA Neurology</i> , 2016, 73, 1115.	9.0	155
72	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. <i>Nature Communications</i> , 2016, 7, 11263.	12.8	73

#	ARTICLE	IF	CITATIONS
73	Characteristics of gliomas in patients with somatic IDH mosaicism. <i>Acta Neuropathologica Communications</i> , 2016, 4, 31.	5.2	29
74	Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?. <i>Neurophysiologie Clinique</i> , 2016, 46, 17-25.	2.2	32
75	Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 47-53.	1.5	15
76	Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation. <i>Neurology</i> , 2016, 86, 912-919.	1.1	33
77	Bevacizumab in late-onset radiation-induced myelopathy. <i>Neurology</i> , 2016, 86, 454-457.	1.1	24
78	Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , 2016, 7, 61916-61929.	1.8	42
79	Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 728-737.	2.5	18
80	Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-7.	1.3	9
81	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2015, 262, 1859-1866.	3.6	105
82	CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 1497-1503.	1.2	52
83	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. <i>Neurology</i> , 2015, 85, 2076-2078.	1.1	28
84	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e166.	6.0	18
85	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	1.5	2
86	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. <i>Cancer Research</i> , 2015, 75, 3519-3528.	0.9	35
87	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. <i>Journal of Neuro-Oncology</i> , 2015, 122, 529-537.	2.9	12
88	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.1	34
89	Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone. <i>Journal of Neurosurgery</i> , 2015, 123, 1244-1246.	1.6	5
90	C inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. <i>Annals of Neurology</i> , 2015, 78, 355-374.	5.3	71

#	ARTICLE	IF	CITATIONS
91	Clinical Spectrum of Encephalitis Associated With Antibodies Against the Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. JAMA Neurology, 2015, 72, 1163.	9.0	123
92	TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications, 2015, 6, 7207.	12.8	42
93	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. Journal of Neuro-Oncology, 2015, 121, 499-504.	2.9	29
94	Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution. Blood, 2015, 126, 1544-1544.	1.4	2
95	Treating glioblastoma patients with poor performance status: where do we go from here?. CNS Oncology, 2014, 3, 231-241.	3.0	3
96	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. BioMed Research International, 2014, 2014, 1-8.	1.9	8
97	Seronegative paraneoplastic cerebellar degeneration: the <scp>PNS E</scp>uronetwork experience. European Journal of Neurology, 2014, 21, 731-735.	3.3	46
98	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology, 2014, 16, 1244-1254.	1.2	47
99	Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology, 2014, 82, 1307-1313.	1.1	43
100	Pontine infarction responsible for wall-eyed bilateral internuclear ophthalmoplegia syndrome. Neurology: Clinical Practice, 2014, 4, 524-525.	1.6	2
101	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro-Oncology, 2014, 16, 662-670.	1.2	59
102	Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 642-648.	1.5	8
103	Patterns of care and survival of glioblastoma patients: A comparative study between 2004 and 2008 in Lyon, France. Revue Neurologique, 2014, 170, 222-227.	1.5	6
104	Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurgical Review, 2014, 37, 415-424.	2.4	37
105	Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82, 556-563.	1.1	202
106	Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. Journal of Infection, 2014, 68, 419-425.	3.3	19
107	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. Expert Opinion on Orphan Drugs, 2014, 2, 831-840.	0.8	0
108	Anaplastic oligodendrogliomasâ€™ value of early chemotherapy. Nature Reviews Neurology, 2013, 9, 7-8.	10.1	3

#	ARTICLE	IF	CITATIONS
109	Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy. Journal of Neuro-Oncology, 2013, 115, 261-265.	2.9	6
110	Dramatic improvement after rituximab in a patient with paraneoplastic treatmentâ€‘refractory <scp>M</scp>orvan syndrome associated with antiâ€‘<scp>CASPR</scp>2 antibodies. European Journal of Neurology, 2013, 20, e96-7.	3.3	23
111	Ventriculitis revealing Bing-Neel syndrome in a patient without Waldenstrom's macroglobulinemia. Clinical Neurology and Neurosurgery, 2013, 115, 82-84.	1.4	10
112	Choosing the tumoral epilepsy surgery candidate. Epilepsia, 2013, 54, 91-96.	5.1	7
113	Predictive biomarkers in adult gliomas. Current Opinion in Oncology, 2013, 25, 689-694.	2.4	34
114	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 2013, 80, 2226-2232.	1.1	68
115	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. Neurology, 2013, 81, 1014-1017.	1.1	25
116	Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse. Blood, 2013, 122, 933-933.	1.4	1
117	Anti-NMDA receptor encephalitis mimicking a primary psychiatric disorder in a 13-year-old girl. Turk Psikiyatri Dergisi, 2013, 24, 145-7.	0.2	0
118	Chemotherapy in low-grade gliomas. Current Opinion in Oncology, 2012, 24, 694-701.	2.4	30
119	A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy. Clinical Cancer Research, 2012, 18, 5071-5080.	7.0	103
120	Quantitative Morphological Magnetic Resonance Imaging Follow-up of Low-Grade Glioma. Neurosurgery, 2012, 71, 729-740.	1.1	116
121	Primary brain tumours in adults. Lancet, The, 2012, 379, 1984-1996.	13.7	723
122	Increased rCBV in status epilepticus. Journal of Neurology, 2012, 259, 1746-1748.	3.6	1
123	Cortical and Subventricular Zone Glioblastoma-Derived Stem-Like Cells Display Different Molecular Profiles and Differential In Vitro and In Vivo Properties. Annals of Surgical Oncology, 2012, 19, 608-619.	1.5	32
124	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. PLoS ONE, 2012, 7, e45950.	2.5	25
125	Antiâ€‘<i>N</i>â€‘methylâ€‘aspartate receptor encephalitis with acute disseminated encephalomyelitisâ€‘like MRI features. European Journal of Neurology, 2012, 19, e16-7.	3.3	36
126	New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary, 2012, 15, 37-43.	2.9	87

#	ARTICLE	IF	CITATIONS
127	Chemotherapy for diffuse low-grade gliomas in adults. <i>Revue Neurologique</i> , 2011, 167, 673-679.	1.5	8
128	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <i>European Journal of Cancer</i> , 2011, 47, 802-808.	2.8	39
129	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 781-789.	2.4	54
130	Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 457-462.	2.9	26
131	Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. <i>Journal of Neuro-Oncology</i> , 2011, 105, 219-224.	2.9	36
132	Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. <i>Journal of Neurology</i> , 2011, 258, 328-329.	3.6	28
133	Encéphalites auto-immunes à anticorps anti-récepteurs-NMDA, une cause fréquente d'encéphalite en réanimation. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2011, 20, 397-407.	0.1	2
134	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. <i>Cancer</i> , 2011, 117, 3014-3026.	4.1	32
135	Peri-ictal pseudoprogression in patients with brain tumor. <i>Neuro-Oncology</i> , 2011, 13, 775-782.	1.2	38
136	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3050-3055.	1.6	196
137	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <i>Neuro-Oncology</i> , 2011, 13, 84-98.	1.2	115
138	Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. <i>Journal of Neuro-Oncology</i> , 2010, 97, 353-364.	2.9	26
139	Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. <i>Journal of Neuro-Oncology</i> , 2010, 100, 439-441.	2.9	15
140	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 937-939.	1.9	31
141	Prognostic markers in gliomas. <i>Future Oncology</i> , 2010, 6, 733-739.	2.4	17
142	Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. <i>Neuro-Oncology</i> , 2010, 12, 1078-1082.	1.2	81
143	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010, 9, 234.	19.2	37
144	Acute Headache Followed by Focal Neuropsychological Impairment in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 75-76.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Glioblastomes: aspects moléculaires et prise en charge actuelle. <i>Oncologie</i> , 2009, 11, 67-71.	0.7	1
146	Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 4150-4154.	1.6	887
147	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , 2009, 21, 537-542.	2.4	40
148	Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.. <i>Blood</i> , 2009, 114, 2702-2702.	1.4	0
149	Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. <i>Journal of Neuro-Oncology</i> , 2008, 88, 185-188.	2.9	10
150	Genomic changes in progression of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 133-140.	2.9	51
151	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. <i>Molecular Cancer</i> , 2008, 7, 41.	19.2	145
152	Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors. <i>Oncologist</i> , 2008, 13, 978-992.	3.7	48
153	Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis. <i>Neuro-Oncology</i> , 2008, 10, 1035-1039.	1.2	29
154	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 606-611.	2.4	56
155	TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 103-107.	1.0	15
156	No association of MDM2 SNP309 with risk of glioblastoma and prognosis. <i>Journal of Neuro-Oncology</i> , 2007, 85, 241-244.	2.9	14
157	Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 325-327.	1.9	41
158	IQGAP1 Protein Specifies Amplifying Cancer Cells in Glioblastoma Multiforme. <i>Cancer Research</i> , 2006, 66, 9074-9082.	0.9	50